Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337709 | 0.83 | CA2 (0.49) | L3MBTL1GAA | |
| SCHEMBL17337705 | 0.83 | CA2 (0.49) | L3MBTL1GAA | |
| SCHEMBL1526467 | 0.79 | GAA (0.57) | GAA | |
| SCHEMBL25327975 | 0.76 | CYP3A4 (0.63) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL15333081 | 0.75 | GAA (0.51) | GAA | |
| SCHEMBL25328758 | 0.74 | CHRNA1 (0.56) | L3MBTL1CTSSCTSK | |
| SCHEMBL3234987 | 0.74 | LMNA (0.63) | L3MBTL1GAA | |
| SCHEMBL30549154 | 0.74 | LMNA (0.63) | L3MBTL1GAA | |
| SCHEMBL16837011 | 0.74 | AKT1 (0.60) | AKT1L3MBTL1CTSSCTSKTACR2 | |
| SCHEMBL17870499 | 0.73 | L3MBTL1 (0.52) | L3MBTL1CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3154997-B1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3154997-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | Novartis AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189791-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | AKT1 3805/4885L3MBTL1 3595/4885CTSS 1929/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | AKT1 2881/4885L3MBTL1 2207/4885CTSS 1673/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | AKT1 2881/4885L3MBTL1 2207/4885CTSS 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.